Compile Data Set for Download or QSAR
Report error Found 800 Enz. Inhib. hit(s) with all data for entry = 7974
LigandPNGBDBM226864(US9328096, 557)
Affinity DataIC50: 1.02nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM227148(US9328096, 836)
Affinity DataIC50: 1.04nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226929(US9328096, 617)
Affinity DataIC50: 1.17nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226759(US9328096, 452)
Affinity DataIC50: 1.43nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226847(US9328096, 540)
Affinity DataIC50: 1.51nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226527(US9328096, 220)
Affinity DataIC50: 1.71nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226611(US9328096, 304)
Affinity DataIC50: 1.71nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226486(US9328096, 179)
Affinity DataIC50: 1.74nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226998(US9328096, 686)
Affinity DataIC50: 1.77nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226353(US9328096, 46)
Affinity DataIC50: 1.81nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226346(US9328096, 39)
Affinity DataIC50: 1.94nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM227052(US9328096, 740)
Affinity DataIC50: 2.02nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226514(US9328096, 207)
Affinity DataIC50: 2.06nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226999(US9328096, 687)
Affinity DataIC50: 2.27nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226472(US9328096, 165)
Affinity DataIC50: 2.45nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226881(US9328096, 574)
Affinity DataIC50: 2.46nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226481(US9328096, 174)
Affinity DataIC50: 2.53nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226483(US9328096, 176)
Affinity DataIC50: 2.60nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226992(US9328096, 680)
Affinity DataIC50: 2.65nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226487(US9328096, 180)
Affinity DataIC50: 2.80nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226807(US9328096, 500)
Affinity DataIC50: 2.84nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226729(US9328096, 422)
Affinity DataIC50: 2.96nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226458(US9328096, 151)
Affinity DataIC50: 2.98nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226485(US9328096, 178)
Affinity DataIC50: 3.05nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226347(US9328096, 40)
Affinity DataIC50: 3.17nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226882(US9328096, 575)
Affinity DataIC50: 3.21nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226874(US9328096, 567)
Affinity DataIC50: 3.22nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM227058(US9328096, 746)
Affinity DataIC50: 3.25nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226529(US9328096, 222)
Affinity DataIC50: 3.37nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226445(US9328096, 138)
Affinity DataIC50: 3.41nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226838(US9328096, 531)
Affinity DataIC50: 3.41nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226521(US9328096, 214)
Affinity DataIC50: 3.63nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226352(US9328096, 45)
Affinity DataIC50: 3.92nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226865(US9328096, 558)
Affinity DataIC50: 4.02nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226477(US9328096, 170)
Affinity DataIC50: 4.03nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226853(US9328096, 546)
Affinity DataIC50: 4.14nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226476(US9328096, 169)
Affinity DataIC50: 4.22nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226879(US9328096, 572)
Affinity DataIC50: 4.36nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226862(US9328096, 555)
Affinity DataIC50: 4.41nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226845(US9328096, 538)
Affinity DataIC50: 4.46nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM227054(US9328096, 742)
Affinity DataIC50: 4.5nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM227000(US9328096, 688)
Affinity DataIC50: 4.56nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226441(US9328096, 134)
Affinity DataIC50: 4.61nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226856(US9328096, 549)
Affinity DataIC50: 4.66nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226494(US9328096, 187)
Affinity DataIC50: 4.67nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226866(US9328096, 559)
Affinity DataIC50: 4.68nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226850(US9328096, 543)
Affinity DataIC50: 4.69nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226465(US9328096, 158)
Affinity DataIC50: 4.71nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226460(US9328096, 153)
Affinity DataIC50: 4.72nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

LigandPNGBDBM226877(US9328096, 570)
Affinity DataIC50: 4.73nMT: 2°CAssay Description:TRKA co-expressed with p75: The assays are based upon DiscoveRx's proprietary Enzyme Fragment Complementation (EFC) technology. In the case of the TR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

Displayed 1 to 50 (of 800 total ) | Next | Last >>
Jump to: